A global pharmaceutical company’s R&D department discovers and develops innovative medicines that ease patients’ suffering and solve the most important unmet medical needs of our time. Researchers in the Antibody Discovery department attempt to solve these problems by targeting specific genetic biomarkers.
Experiments are processed using high-throughput DNA sequencing technologies, also known as Next Generation Sequencing or NGS. Results from NGS machines generate an enormous amount of genetic information and data; sifting through this output is a time-consuming and daunting task.
Researchers encountered several issues when analyzing NGS results: